Roche leads the pack at ECTRIMS with standout data on new MS drug

Roche ($RHHBY) was unquestionably the big winner at last week's multiple sclerosis confab in Europe: Its forthcoming therapy ocrelizumab now boasts data in primary progressive and relapsing remitting forms of the disease, and the drug beat the established therapy Rebif in two of those trials. The company is planning regulatory filings early next year. Report